Amara Maple
The Supreme Court delivered a landmark 7-2 decision last week in Monsanto v. Durnell, effectively eliminating a long-established avenue for individuals to hold pesticide manufacturers accountable in state courts. This ruling curtails the ability of consumers to sue companies for failing to warn them that their products might cause cancer or other serious diseases, particularly when the Environmental Protection Agency (EPA) has not mandated such warnings. The decision has profound implications for product liability law, ongoing mass tort litigation, and the future of consumer protection against potentially harmful chemicals.
The Heart of the Ruling: Preemption Under FIFRA
At the core of the Durnell decision is the legal doctrine of federal preemption, specifically as it applies to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Enacted in 1947 and substantially amended over the years, FIFRA is the primary federal statute governing the registration, distribution, sale, and use of pesticides in the United States. It mandates that all pesticides must be registered with the EPA, which reviews labeling to ensure efficacy and safety, including any necessary warnings.
The Supreme Court’s majority sided with Monsanto (now owned by Bayer), asserting that individuals who develop cancer after using a pesticide are "preempted," or legally prohibited, from suing manufacturers based on a failure-to-warn claim if the EPA had already approved the product’s label without requiring a cancer warning. The Court’s interpretation suggests that state-level failure-to-warn claims are superseded by federal regulatory authority under FIFRA. This effectively insulates manufacturers from liability in state courts for alleged warning deficiencies as long as their product labels comply with EPA requirements.
The Durnell Case and the Shadow of Roundup Litigation
While specific details of the Durnell case itself were not extensively highlighted in public discourse, it served as a pivotal vehicle for the Supreme Court to address the preemption argument. This ruling comes amid tens of thousands of similar cases in lower courts where cancer-stricken plaintiffs are suing Monsanto, alleging that its flagship herbicide, Roundup, caused their non-Hodgkin lymphoma. Failure-to-warn claims have been a foundational element of these lawsuits, making the Durnell decision a critical blow to many plaintiffs’ strategies.
The ruling is widely expected to significantly impede or block similar pending lawsuits seeking compensation for cancers linked to Roundup or other pesticides. Furthermore, it sets a precedent that could bar future comparable cases, potentially reshaping the landscape of product liability for the chemical industry.
A History of Controversy: Glyphosate and Cancer
The active ingredient in Roundup, glyphosate, has been at the center of a protracted scientific and legal debate for years. Introduced by Monsanto in the 1970s, Roundup quickly became the world’s most widely used herbicide. Its ubiquity, particularly with the advent of "Roundup Ready" genetically modified crops, meant widespread exposure for farmers, farmworkers, and consumers.
The controversy intensified in 2015 when the International Agency for Research on Cancer (IARC), a specialized cancer agency of the World Health Organization (WHO), classified glyphosate as "probably carcinogenic to humans." This assessment, based on "limited evidence" of carcinogenicity in humans and "sufficient evidence" in experimental animals, ignited a wave of lawsuits against Monsanto.
Conversely, the U.S. Environmental Protection Agency (EPA) has maintained that glyphosate is "not likely to be carcinogenic to humans" when used according to label instructions. This divergence in scientific opinion between international and national bodies has been a critical point of contention in the litigation, with plaintiffs often citing IARC’s findings and defendants relying on the EPA’s assessment.
Advocacy Groups Condemn the Decision
The Center for Food Safety (CFS), a leading legal nonprofit focused on food and agriculture issues in the U.S., had actively engaged with the Supreme Court in the Durnell case. The organization filed a brief on behalf of a broad coalition of public interest stakeholders, including farmers, farmworkers, medical professionals, consumer protection advocates, and conservationists, urging the Court to uphold the right to sue.
Following the ruling, George Kimbrell, Legal Director at the Center for Food Safety, issued a strong condemnation. "Overturning decades of well-settled law, the Supreme Court eliminated one way the public held pesticide corporations accountable for their products’ harms," Kimbrell stated. He emphasized that while this particular avenue for accountability has been closed, "the fight is far from over." Kimbrell underscored the increased importance of EPA’s role in regulating pesticides and vowed that CFS would continue to hold the agency accountable for public health protection. He also pointed to the ongoing Roundup cancer cases as a clear sign of public frustration with corporate practices that jeopardize health and the environment, calling the decision a "clarion, galvanizing call to continued action" for Americans to demand representatives prioritize health over corporate profit margins.
Industry Cheers, Plaintiffs Recalibrate
The immediate aftermath of the Supreme Court’s decision saw a stark contrast in reactions. Bayer, which acquired Monsanto in 2018 for $63 billion, hailed the ruling as a significant victory. The company’s stock surged by 17 percent on the day of the decision, reflecting investor optimism that the ruling would mitigate future liability and reduce the financial burden of the ongoing lawsuits.
Carey Gillam, editor-in-chief at The New Lede and a prominent investigative journalist and author who has extensively covered the Monsanto/Bayer litigation, offered her expert analysis. In an interview with Corporate Crime Reporter, Gillam noted that Bayer believes the ruling will effectively "put an end to the lawsuits that are still outstanding," making it "much more difficult for the plaintiffs to prevail" without the failure-to-warn claims. She suggested this could lead to more settlements and fewer new lawsuits.
However, Gillam also highlighted that not all plaintiffs’ attorneys are conceding defeat. Some maintain that they can still pursue claims based on other grounds, such as negligence or design defects, arguing that the product was inherently dangerous or improperly designed, irrespective of warnings. Yet, Gillam cautioned that while such claims are still possible, the removal of the failure-to-warn argument significantly complicates litigation strategy.
"From what I’ve seen attending a lot of these trials and reading the transcripts and writing a book about this, the failure to warn claim is something that is foundational to much of this litigation," Gillam explained. "It’s easy for juries to understand. Here is the science, there is abundant scientific research out that shows a connection, that shows that at least it’s possible. You have the WHO classification. Why didn’t the company put that on the product, like a tobacco warning label? That resonated with jurors. I have interviewed several of them."
Gillam elaborated on the practical implications for legal teams: "When you take that away and start arguing the technicalities of the design defect claim, it does whittle away at the ease with which juries understand these cases." She also pointed out the immense financial investment required to bring these cases to trial, often millions of dollars per firm. The prospect of reduced punitive damages, which were often tied to the perceived egregious nature of withholding warnings, could deter law firms from taking on new cases, pushing them towards more financially rewarding endeavors.
The dissenting justices, Gorsuch and Brown Jackson, articulated concerns that the majority’s interpretation of FIFRA was an inaccurate reading of the law, suggesting a highly politicized ruling that disregarded nuances in the statutory language.
The Broader Litigation Landscape: Settlements and Divisions
The Roundup litigation has been a massive undertaking, involving an estimated 170,000 cases at its peak. While the majority have been resolved, Bayer estimates 50,000 to 60,000 claims may still be outstanding. The company has already paid over $11 billion towards these cases, with individual trials sometimes resulting in punitive damages in the billions or hundreds of millions of dollars, though Bayer also secured victories in many cases.
The litigation has largely proceeded through a multi-district litigation (MDL) framework rather than a traditional class action. In an MDL, individual cases from across the country are consolidated before a single federal judge for pretrial proceedings like discovery and expert witness depositions, streamlining the process. However, each case retains its individual identity and, if not settled, typically returns to its home court for trial. Judge Vince Chhabria in California has overseen the Roundup MDL since its inception.
Parallel to the individual MDL cases, Bayer has been actively pursuing a class action settlement. This proposed settlement aims to resolve claims from all individuals who are currently suing, intend to sue, or may develop cancer and wish to sue in the future, placing them into a single "bucket" with tiered payouts. Bayer has offered another $7.25 billion to settle these class action lawsuits.
This class action proposal has been met with significant controversy and animosity, particularly among plaintiffs’ attorneys. The deal was reportedly brokered between Bayer and a select group of plaintiffs’ attorneys who were less involved in the initial, hard-fought trials. Judge Chhabria, overseeing the MDL, publicly criticized the proposed class action settlement as "filthy" and "very unfair," particularly given the potentially meager payouts of a few thousand dollars for plaintiffs, contrasted with an estimated $600 million for the settling attorneys. This sentiment is widely shared by the lead law firms who invested years and substantial resources in building the initial cases and securing large verdicts, as they are not part of the class action settlement.
The Supreme Court’s preemption ruling adds another layer of complexity to these ongoing settlement negotiations. Plaintiffs who had been holding out for stronger individual trial outcomes based on failure-to-warn claims now face a weakened legal position, potentially pushing more individuals to consider the class action settlement, despite its perceived shortcomings. A crucial hearing on the class action settlement is scheduled for July 9, where the number of plaintiffs opting in or out will become clearer, potentially determining whether Bayer proceeds with the deal.
Legislative Pushback and Future Challenges
The Supreme Court’s decision has immediately spurred calls for legislative action to restore the right to sue. Senator Cory Booker and Congresswoman Chellie Pingree, among others, are advocating for amendments to FIFRA that would explicitly state that federal pesticide regulations do not preempt state-level failure-to-warn claims. Congresswoman Pingree has already introduced legislation to this effect, and Senator Booker has explored adding a similar amendment to the Farm Bill.
However, the path to legislative reform is fraught with challenges. The agricultural chemical industry maintains a powerful lobbying presence in Washington D.C., and overturning a Supreme Court decision through legislation requires significant political will and broad bipartisan support. Advocates, including the "Make America Healthy Alliance" (MAHA) and grassroots organizations, are mobilizing, threatening to make this a key issue in upcoming elections, hoping to exert pressure on representatives to prioritize public health over corporate interests.
Beyond Roundup: The Paraquat Parallel
The implications of the Durnell ruling extend beyond Roundup, casting a long shadow over other ongoing mass tort litigations involving pesticides. Carey Gillam pointed to the Paraquat litigation as a significant area to watch. Paraquat, another widely used weedkiller, is currently the subject of an MDL where plaintiffs allege it causes Parkinson’s disease.
Gillam highlighted concerns in the Paraquat MDL, where Judge Nancy Rosenstengel is reportedly attempting to encourage plaintiffs to accept a settlement offer from Syngenta that plaintiffs’ lawyers deem "pitiful." Gillam noted the unusual pressure tactics, where the judge is allegedly requiring plaintiffs who refuse the settlement to undergo extensive scrutiny, including depositions and meetings with a special master. This raises questions about judicial impartiality and the extent to which judges can influence settlement decisions, particularly when plaintiffs are dealing with debilitating illnesses.
The Monsanto v. Durnell decision marks a pivotal moment in American product liability law. While celebrated by industry and investors, it has been met with dismay by consumer advocates and many plaintiffs. It signals a shift in accountability, placing greater emphasis on federal regulatory bodies like the EPA and challenging victims of alleged corporate negligence to find new legal strategies. The long-term ramifications will unfold in courtrooms, legislative halls, and potentially, at the ballot box, as the battle for corporate accountability in the face of public health concerns continues.
Joko Widodo
admin
Nila Kartika Wati
Yuyun Lusiyani
Pevita Pearce
Nana Wu